Pembrolizumab
SMARCA4-Deficient Tumor
Eli Lilly and Companymonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the SMARCA4-Deficient Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Zhijie Wang | Phase 2 | B |
CIS-DIAMMINEDICHLOROPLATINUM II Eli Lilly and Company | Phase 1 | CC |
ly4050784 Eli Lilly and Company | Phase 1 | CC |
Same molecule, other indications
Pembrolizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →